A citation-based method for searching scientific literature


List of co-cited articles
335 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
156
28

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
320
26

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
658
26

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
272
24

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Songping Han, Deborah L Hagan, Joseph R Taylor, Li Xin, Wei Meng, Scott A Biller, John R Wetterau, William N Washburn, Jean M Whaley. Diabetes 2008
252
22

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
L Thomas, R Grempler, M Eckhardt, F Himmelsbach, A Sauer, T Klein, P Eickelmann, M Mark. Diabetes Obes Metab 2012
39
25

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
146
20

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Ravindar N Girotra, Gang Wu, Philip M Sher, Eamonn P Morrison, Scott A Biller,[...]. J Med Chem 2008
327
18

SGLT2 mediates glucose reabsorption in the early proximal tubule.
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J Am Soc Nephrol 2011
278
18

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
Hassan Rahmoune, Paul W Thompson, Joanna M Ward, Chari D Smith, Guizhu Hong, John Brown. Diabetes 2005
459
18

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
R A DeFronzo, J A Davidson, S Del Prato. Diabetes Obes Metab 2012
294
18

Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
449
16

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Sumihiro Nomura, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Yuichi Koga, Toshiaki Sakamoto, Yasuo Yamamoto, Kiichiro Ueta, Hirotaka Kimata, Keiko Nakayama,[...]. J Med Chem 2010
182
16

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
16

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
139
14

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, Tonya Martin, Fuyong Du, Yi Liu, June Xu, Bruce Conway,[...]. PLoS One 2012
151
14


Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
647
14

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Raktim Kumar Ghosh, Samhati Mondal Ghosh, Shalini Chawla, Sarfaraz Abdeli Jasdanwala. J Clin Pharmacol 2012
55
14

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
T Heise, E Seewaldt-Becker, S Macha, S Hantel, S Pinnetti, L Seman, H J Woerle. Diabetes Obes Metab 2013
168
14


Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
417
12

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima, Ikumi Nakashima, Shigeru Nakano, Yukiko Ishikawa-Takemura, Hiroshi Kusama, Masayuki Isaji. Eur J Pharmacol 2009
50
12

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
L Rossetti, D Smith, G I Shulman, D Papachristou, R A DeFronzo. J Clin Invest 1987
521
12

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
146
12


Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa, Kazuharu Ozawa, Hitoshi Hagita, Takahiro Kawai, Minako Takeda, Tatsuo Yata, Mio Kawai, Taku Fukuzawa,[...]. J Pharmacol Exp Ther 2012
96
12

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
René Santer, Joaquim Calado. Clin J Am Soc Nephrol 2010
186
12

Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Sunder Mudaliar, Debra A Armstrong, Annie A Mavian, Robin O'Connor-Semmes, Patricia K Mydlow, June Ye, Elizabeth K Hussey, Derek J Nunez, Robert R Henry, Robert L Dobbins. Diabetes Care 2012
32
18

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
12

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
473
12



Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
466
12

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
151
12

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Elizabeth M Lamos, Lisa M Younk, Stephen N Davis. Expert Opin Investig Drugs 2014
27
22



Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Masahiro Hiratochi, Fumiaki Itoh, Yoshimitsu Komatsu, Hideki Fujikura, Masayuki Isaji. J Pharmacol Exp Ther 2007
174
10

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion.
Valentin Gorboulev, Annette Schürmann, Volker Vallon, Helmut Kipp, Alexander Jaschke, Dirk Klessen, Alexandra Friedrich, Stephan Scherneck, Timo Rieg, Robyn Cunard,[...]. Diabetes 2012
377
10


Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo. Diabetes 2012
122
10


Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
10

Renal Na(+)-glucose cotransporters.
E M Wright. Am J Physiol Renal Physiol 2001
353
10


Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
294
10

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon. Am J Physiol Renal Physiol 2014
142
10

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
E Ferrannini, L Seman, E Seewaldt-Becker, S Hantel, S Pinnetti, H J Woerle. Diabetes Obes Metab 2013
123
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.